D. Messeri

Postprandial glucose monitoring in type 1 diabetes mellitus: use of a continuous subcutaneous monitoring device

L. V. Van Gaal, J. Vertommen, I. D. De Leeuw, 2004, Diabetes/metabolism research and reviews.

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.

M. Burotto, L. Fallowfield, S. Margolin, 2021, European journal of cancer.

165MO Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study

M. Burotto, L. Fallowfield, J. O’Shaughnessy, 2020 .

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

W. Hiddemann, A. Schuh, P. Johansson, 2018, Haematologica.

A stable, high relaxivity, diaqua gadolinium complex that suppresses anion and protein bindingElectronic supplementary information (ESI) available: pH dependence of europium emission spectra, stability screening details and relaxivity/pH plots for selected Gd complexes. See http://www.rsc.org/suppda

Mauro Botta, M. Botta, David Parker, 2001 .

Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukemia: primary results from the randomised phase IIIb MABLE study

W. Hiddemann, A. Schuh, P. Johansson, 2015 .

A novel continuous subcutaneous lactate monitoring system.

F. Ricci, D. Moscone, F. Valgimigli, 2005, Biosensors & bioelectronics.

Novel planar glucose biosensors for continuous monitoring use.

F Valgimigli, F Ricci, F. Ricci, 2005, Biosensors & bioelectronics.